Lyra Therapeutics Inc at H C Wainwright Global Investment Conference (Virtual) Transcript
Good afternoon, everyone, and thank you for joining H.C. Wainwright's 24th Annual Global Investment Conference. I'm Jennifer (inaudible), an associate at H.C. Wainwright. And I'd like to introduce our presenter, Maria Palasis of Lyra Therapeutics.
Thank you, Jennifer, and thank you for the invitation to present today. It's an exciting time for Lyra. We are in our pivotal program currently. Our first indication is for chronic rhinosinusitis. It's an enormous unmet need with millions of patients. 10% of the US population have this disease. And our product is a drug delivery system that uses a known anti-inflammatory drug, which we view as highly de-risked. This is our disclaimer. It's also on our website.
So Lyra has developed a platform that is able to target drugs directly to tissues in a very consistent way, which enables us to treat chronic diseases. Our first indication is for chronic rhinosinusitis. These are patients that have
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |